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ABSTRACT OF DISSERTATION 
 
OVARIAN HORMONES, ADHD, RISK-TAKING,  & IMPULSIVITY 
 
Attention-Deficit/Hyperactivity Disorder (ADHD) is a highly impairing disorder of 
inattention, hyperactivity, and impulsivity that is more frequently diagnosed in males 
versus females at a ratio of 3:1. However, females with the disorder become highly 
impaired during adolescence, perhaps due to the onset of cycling ovarian hormones at 
puberty. The present study empirically assessed the role of the major female sex 
hormones, estrogen and progesterone, in the presentation of ADHD symptoms, 
impulsivity, and associated risk-taking behaviors (e.g., risky sex, substance use and 
abuse) in a non-clinical sample of young adult women. 32 healthy young adult women 
who were screened for hormonal conditions and medication use completed an initial 
laboratory visit during which measures of impulsivity and ADHD symptoms were 
collected. Each morning for 35 subsequent days, participants’ hormones were measured 
via passive drool saliva samples, and participants responded to a brief online survey 
regarding substance use and sexual behaviors for the last 24 hours. Each evening, 
participants completed online questionnaires regarding ADHD symptoms. Results 
showed that ADHD symptoms were most pronounced when estrogen was low; this 
association manifested (1) between women, with lower average estrogen across the entire 
cycle predicting higher ADHD symptoms, and (2) within women, with lower-than-
average levels of estrogen during periods of higher-than-average progesterone predicting 
higher ADHD symptoms two days later, consistent with a post-ovulatory, luteal phase 
effect of estrogen. Moderation analyses revealed that these within-person effects of 
ovarian hormones were significant only among women with high negative or positive 
urgency (emotion-related impulsivity) or high sensation seeking. With regard to alcohol 
use, within-person results were somewhat different; higher-than-average within-person 
estrogen was associated with higher likelihood of drinking and binge drinking on the 
following day, and this was true only during periods of lower-than-average progesterone, 
consistent with a pre-ovulatory, follicular phase effect of estrogen. These results have 
implications for the conceptualization of ADHD and associated risk-taking behaviors 
such as drinking, including personalization of treatment approaches for women.  
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CHAPTER ONE: INTRODUCTION 
Background 
	  
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common and highly 
impairing childhood neurodevelopmental disorder (APA, 2013; Bernfort, Nordfeldt, & 
Persson, 2008; Pelham, Foster, & Robb, 2007, Polanczyk, de Lima, Horta, Biederman, & 
Rohde, 2007) that often persists into adolescence and adulthood (Faraone & Biederman, 
2005; Kessler et al., 2006). The prevalence rate of ADHD in adults is thought to be 
between 3 and 5% (Faraone & Biederman, 2002; 2005; Kessler et al., 2006; Wilcutt, 
2012). Adults with ADHD are at an increased risk for engaging in behaviors with 
negative outcomes and high societal cost, such as substance abuse, promiscuous sexual 
activity, and increased vehicular accidents, and are at increased risk for anxiety and mood 
disorders (Bauermeister et al., 2007; Barkley, 2006; Hosain, et al., 2012; Loe & Feldman, 
2007; Flory, Molina, Pelham, Gnagy, & Smith, 2006; Wehmeier, Schacht, & Barkley, 
2010).  One of the most noted features of ADHD is that it is more frequently diagnosed in 
male children at a ratio of 3:1; yet females with the disorder are often particularly highly 
impaired beginning during adolescence and into adulthood (Lahey, et al. 1994), 
exhibiting such negative outcomes as poor self esteem, increased rates of anxiety and 
depression, and unplanned pregnancies (Biederman et al., 1999; Hosain, et al., 2012; 
Quinn, 2005, Robison et al., 2008). Further, there appear to be sex differences in 
symptom expression such that males with ADHD are more likely to exhibit 
hyperactivity-impulsivity and comorbid disruptive behavior disorders during childhood, 
while females with ADHD are more likely to exhibit inattention and comorbid depression 
during adolescence (Gaub & Carlson, 1997; Gershon & Gershon, 2002).  
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Yet, mechanisms of sex differences in symptom expression and comorbidity 
remain unknown, despite the fact that changes in sex, or gonadal hormones, during the 
prenatal period and adolescence may likely play a role. Initial work, in fact, suggests a 
role for prenatal testosterone exposure and ADHD (Martel, 2009; McFadden et al., 2005; 
Roberts & Martel, 2013).  Such work suggests that known markers of symptoms and 
pathways to ADHD such as cognition and traits can help shed light on hormonal 
mechanisms. The current project focuses on ADHD symptoms, specific markers of 
disorder including cognition (executive function), risk-taking (drug abuse), and 
impulsivity (urgency), and circulating hormones during adolescence and young adulthood 
as a particularly understudied and yet critically important developmental risk factor for 
ADHD. The only existing work on hormonal associations with ADHD symptoms in 
adulthood relied on case studies which suggest that ADHD symptoms may fluctuate 
across the menstrual cycle, worsening the week before menstruation (when both estrogen 
and progesterone are declining; Quinn, 2005) and with symptom relief during pregnancy, 
a time of dramatically increased estrogen and progesterone (Nadeau & Quinn, 2002). 
Yet, no work to date has directly examined hormone levels themselves and their 
relationship to ADHD symptoms in groups of women, the goal of the current project. 
Ovarian Hormonal Effects 
	  
Given that females with ADHD exhibit striking impairment beginning during 
adolescence, dramatic rises and fluctuations in sex hormones at puberty might play a role 
in this phenomenon. Beginning just before puberty, which typically occurs between 9 and 
14 in human females (Norman & Litwack, 1997), both estrogen (E2) and progesterone 
(P4) rise and then begin to fluctuate across the monthly female reproductive cycle, as 
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shown in Figure 1 (Norman & Litwack, 1997). Generally speaking, in a typical 28-day 
cycle, E2 and P4 are both low during the week or so following the onset of menstruation, 
known as the early follicular phase. While P4 remains low throughout the remainder of 
the follicular phase, about eight days after the onset of menses, E2 begins rising steadily, 
reaching its peak around ovulation (occurring, on average, around 14 days prior to the 
onset of the next menses), alongside a more notable peak in lutenizing hormone, which 
marks the beginning of the luteal phase (Mishell et al., 1971; Norman & Litwack, 1997; 
see Figure 1). Notably, most variation in cycle length is attributable to the follicular phase 
of the menstrual cycle, with the luteal phase demonstrating much greater stability (~14 
days). For example, stress can lengthen the follicular phase of the cycle, while the luteal 
phase of the cycle is much more consistent in length (Fehring, Schneider, & Raviele, 
2006; Norman & Litwack, 1997). 
 This second half of the cycle (after ovulation) is called the luteal phase. 
Immediately following ovulation, E2 first declines rapidly before exhibiting a second 
smaller rise along with increasing P4 levels, which reach an all time high around mid-
luteal phase. At the end of the luteal phase, both E2 and P4 decline rapidly a few days 
before the onset of the next menses (Norman & Litwack, 1997).  Yet, it cannot be 
stressed enough that this typical pattern can vary greatly within women and between 
women on a month-to-month basis (Treloar, Boynton, Behn & Brown, 1967). For 
example, women exhibit striking variability in their levels of E2 and P4, as well as in the 
length of their cycle, even from month to month (Chatterton et al., 2005; Fehring, 
Schneider, & Raviele, 2006). In addition, individual women exhibit striking variation in 
their levels across the menstrual cycle with inter- and intra-person variation in the 
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magnitude of surges and declines (Chatterton et al., 2005). Further, after puberty, the 
menstrual cycle can take several years to become the fairly regular average of 28 days it 
is for most adult females (Norman & Litwack, 1997; Treloar, Boynton, Behn & Brown, 
1967).  
Cyclical hormonal patterns and levels change across development.  Before 
puberty, gonadal hormones including E2 and P4, as well as testosterone, remain fairly 
low and static (Norman & Litwack, 1997). However, as puberty approaches, levels of 
gonadal hormones rise and, in women, begin to fluctuate in the cyclical manner described 
above (Norman & Litwack, 1997). Yet, this regular pattern often does not stabilize for 
several years. Furthermore, pregnancy, menopause, endocrine disease, use of oral 
contraceptives, use of steroid medication, body mass index, and even stress can impact 
hormone levels (Dobson & Smith, 2000; Gaspard et al., 1983; Lukanova et al., 2004; 
Nelson, 2011; Norman & Litwack, 1997; Pastor, Griffin-Korf, Aloi, Evans, & Marshall, 
1998; Van der Vange, Blankenstein, Kloosterboer, Haspels, & Thijssen, 1990; Weiner, 
Primeau, & Ehrmann, 2004).  
Yet, hormone levels and the more typical study of phase effects appear to be 
strikingly important for understanding female mood (which has been heavily studied; 
Eisenlohr-Moul, DeWall, Girdler & Segerstrom, 2015; Nelson, 2011; Payne, 2003; 
Steiner, Dunn, & Born, 2003; Vesco, Haney, Humphrey, & Nelson, 2007; Walf & Frye, 
2006; Weiner, Primeau, & Ehrmann, 2004), as well as other affective processes, 
including impulsivity (Klump et al., 2014; Rosenblitt, Soler, Johnson and Quadagno, 
2001).  Yet, perhaps because of the complexity of such effects, hormonal influences on 
 
	   5	  
these constructs remain relatively understudied and have never been directly studied in 
relation to ADHD in particular (Nussbaum, 2012).  
Ovarian Hormonal Associations with Problems Related to ADHD 
The fact that circulating hormone levels are dramatically understudied in relation 
to ADHD symptoms in females is particularly surprising given their known roles in 
associated processes such as executive function (EF), risk-taking, and response to 
psychostimulants. Deficits in executive function (e.g. problem-solving to achieve a future 
goal, including working memory, inhibition) are commonly associated with ADHD, 
occurring in at least 50% of individuals with an ADHD diagnosis (Willcutt, Doyle, Nigg, 
Faraone, & Pennington, 2005). Higher levels of both E2 and P4 have been individually 
linked to enhanced EF and attention (e.g., Davis & Nolen-Hoeksema, 2000; Hatta & 
Nagaya, 2009; Segerstrom, Roach, Evans, Schipper, & Darville, 2010). Several aspects 
of EF appear to be improved when E2 and P4 levels are high (Gogos, 2013; Howard, 
Gifford, & Lumsden, 1988; Jacobs & D’Esposito, 2011; Lord & Taylor, 1991; Rosenberg 
& Park, 2002; Segal, 2012; Vranic ́ & Hromatko, 2008; Solís-Ortiz & Corsi-Cabrera, 
2008; Solis-Ortiz, Guevara, & Corsi- Cabrera, 2004). For example, a study of naturally 
cycling young adult women (age 18-28), suggested a positive association between the 
follicular phase (when E2 is typically high) and executive functions that are “typical 
female” strengths. More specifically, women in the follicular phase demonstrated better 
performance on tasks of verbal implicit memory and verbal fluency, but worse 
performance on tasks involving mental rotations and perceptual priming  (Maki, Rich & 
Rosenbaum, 2002). Thus, E2 appears to facilitate most types of EF.  
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Studies also demonstrate worsening memory and sustained attention during 
menopause (Frankiewicz & Cutler, 2000; Schmidt et al., 1996), a period characterized by 
a significant decrease in and destabilization of ovarian hormones. Likewise, a study in 
post-menopausal elderly women demonstrated that low doses of E2 might improve brain 
function efficiency during the tasks of sustained attention (Stevens, Clark & Prestwood, 
2005). Finally, experimental administration of either E2 or P4 following pharmacological 
hormone suppression normalizes neural activity associated with executive functioning 
(Berman et al., 1997).  Thus, overall, results are consistent with the idea that high levels 
of E2 are associated with better EF, including working memory and attention, two EFs 
that appear to be related to symptoms of ADHD. 
In addition to the higher prevalence of EF deficits, individuals with ADHD also 
engage in higher levels of risk-taking than their peers (which in adulthood often 
manifests as substance abuse and risky sexual behaviors (Barkley, Murphy, & Fischer, 
2010; Biederman et al., 2002; Disney et al., 1999; Wilens, Spencer, & Biederman, 1995). 
In some studies, cyclical “lows” of both E2 and P4 (measured via cycle phase and 
hormone levels) appear related to increased risk for alcohol and tobacco abuse 
(Carpenter, Upadhyaya, LaRowe, Saladin, & Brady, 2006; Evans & Levin, 2011; Epstein 
et al., 2006; Franklin et al., 2004, 2008; Pastor & Evans, 2003; Schiller, Saladin, Gray, 
Hartwell, & Carpenter, 2012). Yet, the subjective effects of stimulants (e.g. cocaine, 
methamphetamine) appear to have the opposite pattern of association with hormones, 
such that women report greater subjective effects of stimulants during the follicular phase 
(when E2 is rising and P4 is at low, at almost undetectable levels) compared to the luteal 
phase, when P4 is high and E2 is moderate (Sofuoglu, Dudish-Poulsen, Nelson, Pentel & 
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Hatsukami, 1999; Terner & de Wit, 2006). Pre-treatment with E2 also increases some of 
the subjective effects of stimulant medications (Justice & deWitt, 1999; 2000, White, 
Justice & de Wit, 2002), whereas high levels of P4 and administration of P4 attenuate the 
subjective effects of stimulants, minimizing the effects of E2 on stimulant effects during 
the luteal phase (Evans, 2007; Justice & deWitt, 1999). In line with hormonal effects on 
alcohol and nicotine use, lower E2 has also been associated with increased risk-taking as 
measured by monetary risk tasks, trust of strangers during an investment game, and 
measures of real-life risky behaviors, all of which demonstrated that women were less 
cautious (i.e., took more risks) during phases when levels of E2 were low, as measured 
by counting cycle days (Ball et al., 2013; Broder & Hohmann, 2003; Kaighobadi & 
Stevens, 2013).  
Taken together, these studies suggest that low levels of E2 may be risky for 
increased use of and cravings for substances such as alcohol. Yet, the effects of other 
stimulants (e.g. cocaine, amphetamines) appear to be enhanced by E2 such that they are 
more rewarding to utilize when E2 is high and P4 is low (i.e. the follicular phase). Due to 
the higher incidence of risk-taking and substance use among women with ADHD, it is 
possible that women at risk for the disorder have lower average levels of E2 that put them 
at risk for use of alcohol. Thus, lower average E2 may represent a pathway to both 
substance use and ADHD symptoms in some women.  
ADHD Heterogeneity 
	  
Recent theory of ADHD defines it as a disorder of disinhibition (Barkley, 1997; 
Nigg, 2001), and impulsivity is a core component based on ADHD diagnostic criteria. 
Yet, one of the most striking features of the disorder is its heterogeneity, which is 
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currently described using three subtypes, or presentations. Likewise, recent theory of 
ADHD suggests multiple pathways to the disorder (Nigg, Goldsmith, & Sachek, 2004; 
Sonuga-Barke, 2005), with continuous symptom dimensions perhaps best supported 
(Haslam et al., 2006; Larsson, Anckarsater, Råstam, Chang, and Lichtenstein, 2012; 
Marcus & Barry, 2011). In adulthood, one potentially particularly promising way of 
doing this is by focusing on impulsivity, which seems to be particularly prominent in 
adulthood (Barkley, Murphy, & Fischer, 2010). Notably, conceptualization of impulsivity 
has advanced in recent years (Lynam, Smith, Whiteside, & Cyders, 2006; Smith et al., 
2007).  
A handful of studies on such conceptualizations of impulsivity in adults with 
ADHD suggest associations with Lack of Perseverance (inability to remain with a task 
through completion), Negative Urgency (negative affect-driven rash action), and Lack of 
Planning (action without careful thinking; Miller et al., 2010; Pedersen et al., 2016; 
reviewed by Berg, Latzman, Bliwise, & Lilienfeld, 2015). Sensation Seeking (tendency 
to seek adventure) may be more specifically associated with hyperactivity-impulsivity 
(Lopez et al., 2015). Further, Urgency, Sensation-Seeking, and Lack of Planning appear 
to explain associations between ADHD and substance use (Pedersen et al., in press; 
Roberts et al., 2014). These studies suggest that trait impulsivity appears to be related to 
ADHD, and those who are high in certain forms of trait impulsivity may be more likely 
to experience risk-taking behaviors (e.g., substance use). According to an interactional 
perspective on personality (Endler & Parker, 1992), impulsive action (i.e. risk taking 
behaviors) are dependent on an individual’s personality in addition to interactions with 
other factors, including social, environmental or biological factors (Endler & Parker, 
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1992). Therefore, studies examining hormonal associations with ADHD in young adult 
women may need to pay particular attention to impulsivity as a moderator of hormonal 
effects since these effects may interact and effects may be particularly striking for young 
women high in trait impulsivity.  
Goals of the Present Study 
	  
To recap, although lower E2 appears to be associated with worse EF and more 
risk taking (e.g., substance use), no empirical work to date has directly examined the role 
of circulating E2 in relation to ADHD symptoms and associated markers. Further, 
specific types of trait impulsivity may help explain heterogeneity within ADHD in adults; 
yet, thus far, these ideas have not been examined. 
The present study sought to examine the association between ovarian hormone 
levels, ADHD symptoms, and risk-taking behaviors (i.e., substance use), and to explore 
whether associations between ovarian hormones and ADHD symptoms and risk-taking 
behaviors are moderated by trait impulsivity. Based on prior work suggesting that higher 
E2 has positive effects on EF and decreases risk for more common forms of substance 
use (i.e., alcohol), it was hypothesized that, 1) between-women, lower average E2 across 
the entire menstrual cycle (i.e. higher overall recent exposure to E2) would be associated 
with greater ADHD symptoms and risky behaviors, 2) lower-than-average (within-
person) levels of E2 would be associated with increases in ADHD symptoms and risky 
behaviors, and that 3) lower-than-average (within-person) levels of E2 would be more 
strongly associated with increased ADHD symptoms and risk-taking for those with 
higher levels of trait impulsivity. Additionally, given the potential for interactive effects 
of E2 and P4 (Klump et al., 2008; 2013; Eisenlohr-Moul et al., 2015), P4 was included as 
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an exploratory variable, and examined as a moderator of E2 effects. Finally, phase effects 
were also examined in order to more easily compare study results to previous studies that 
utilized cycle phase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Typical representation of expected E2 and P4 levels across the cycle (Haimov-
Kochman & Berger, 2007). The boxes indicate periods of the cycle hypothesized to 
exhibit increases in ADHD symptoms and risk-taking behaviors.  
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CHAPTER TWO: METHODS 
Overview of Study Design 
	  
 The study design was short-term longitudinal. Participants completed a screening 
visit to determine study eligibility. The women eligible to participate in the current 
project subsequently completed 35 sequential days of in-home data collection lasting 30-
45 minutes each day. Hormones were assayed every other day, resulting in an average of 
17 observations per woman. 
Participants 
	  
Participants were a non-clinical sample of 32 naturally-cycling young women 
between the ages of 18 and 22 (M = 19.43, SD = 1.38) that were undergraduates recruited 
from the University of Kentucky Psychology Department subject pool and young women 
from the community recruited via posted flyers. The participants’ ethnic background 
broadly matched that of the surrounding community; 70.6% of the sample identified as 
Caucasian, 17.6% as African American, and 11.8% as another ethnic minority.  
Procedure 
 Screening and Initial Lab Visit. All participants completed one in-lab screening 
visit where they provided informed consent via IRB-approved procedures. The 32 
eligible females completed 35 sequential days of follow-up data collection at home. 
Study eligibility was assessed at the initial screening visit. All participants completed the 
Screening and Medical History Form (detailed below), and a measure of study eligibility, 
with a trained study staff member. Participant’s height and weight were also measured 
since body mass index has been demonstrated to have an effect on circulating levels of 
sex-steroid hormones (Lukanova et al., 2004; BMI Mean = 24.37, SD = 6.33).  Finally, 
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participants completed measures of trait impulsivity, ADHD symptoms, and executive 
functioning at this initial visit (detailed below). 
To be eligible for the study, participants had to be female and between 18 and 24. 
Exclusionary criteria included primary sensorimotor handicap, neurological disorder 
(e.g., seizure disorders, brain tumor, cerebral palsy, hydrocephalus, head injury with loss 
of consciousness), known pervasive developmental disorder (i.e., autism, Asperger’s, 
Rett’s, childhood disintegrative disorder), reported psychosis (i.e., schizophrenia, 
hallucinations, delusions), diagnosed intellectual disability, known hormonal 
abnormalities (e.g., Polycystic Ovarian Syndrome, thyroid conditions), including 
irregular cycles (i.e., cycles shorter than 21 days or longer than 35 days or fluctuating by 
more than 10 days across cycles, per self report), and current medical use of hormonal 
preparations (e.g., oral contraceptives, steroid-based medications), psychostimulants, or 
antipsychotic medications. Other medication use was measured in an open-ended 
manner; three women reported using prescribed Selective Serotonin Reuptake Inhibitors 
(SSRIs). However, SSRI use was not associated with outcomes or average hormone 
levels across the cycle (all p’s < .34). Participants who met study exclusionary criteria 
were invited to complete the 35-day study. Forty-eight women were eligible and began 
data collection. However, 23% (N=11) discontinued participation during the study and 
10% (N=5) completed less than 50% of data collection, leaving a final sample size with 
usable data of 32 women.  
Eligible and interested female participants were sent home with a packet of data 
collection materials so they could collect data every day for the following 35 days. 
Detailed instructions on at-home data collection were provided verbally and in writing, 
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and participants were provided with the telephone number and email address of a trained 
research assistant in case they had any questions. They also provided a telephone number 
and email address so that they could receive daily reminders about data collection and 
links to morning and evening surveys throughout the 35 days. Every morning, 
participants provided saliva samples (described below), and responded to a short 
questionnaire about psychotropic medication use and food intake. All participants 
reported taking some form of medication over the course of the study. The most common 
included over-the-counter medications for pain, gastrointestinal distress, cold and flu, and 
allergies. None of the participants reported eating immediately upon waking, suggesting 
that saliva collection directions were followed. 
At this time, participants also completed a measure of drinking, described below. 
In the evening after 5pm, they were instructed to follow an email link to a secure website 
to complete 30-45 minutes of questionnaires (described below) which are time- and date-
stamped so accuracy of data collection could be monitored. Timestamps suggested that 
data were collected appropriately (e.g. morning surveys completed in morning and 
evening surveys completed same-day after 5pm). At the end of the 35 days, study staff 
contacted participants and arranged for a time for them to return their frozen saliva 
samples to the laboratory for storage in an -80 degree freezer. Participants who completed 
any data collection received $50 compensation, those who completed >50% of the data 
received $75, and those who completed all data collection received $100. Following the 
end of data collection, saliva samples were sent in bulk to the Center for Clinical and 
Translational Science (CCTS) on the University of Kentucky campus for at-cost assaying 
with well-established and reliable assays (described below).  
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Measures 
	  
ADHD Symptoms. Participants completed the Current ADHD Symptoms Scale 
(CSS): Self-report, a symptom checklist for ADHD, Oppositional-Defiant Disorder 
(ODD), and Conduct Disorder (CD) symptoms and associated impairment (Barkley & 
Murphy, 2006) at the screening visit and for the next consecutive 35 days. Symptom 
counts were used for analysis rather than diagnosis, as the sample was community-
recruited and research indicates that ADHD is best represented as a continuum (vs. 
category; Barkley, 2006; Haslam et al., 2006; Marcus & Barry, 2011). Second reporter 
responses for childhood symptoms were received for 34% of participants (N=11), and 
indicated that only one participant experienced a clinically significant number of ADHD 
symptoms (5 inattentive and 3 hyperactive-impulsive symptoms) during childhood. 
Second reporter responses for current symptoms were received for 41% of participants 
(N=13) and reports of both childhood and adult symptoms were received from 28% of 
participants (N =9). Based on self and second reporter responses, none of the participants 
met DSM-5 criteria for ADHD. Total possible daily (state) reported ADHD symptoms 
ranged from 0 to 18 (M = .52, SD = 1.40; α = .80). Total possible Hyperactive-Impulsive 
symptoms ranged from 0 to 9 (M = .32, SD = .66; α = .66), and possible Inattentive 
symptoms ranged from 0 to 9 (M = .20, SD = .65; α = .72).  Data screening revealed that 
symptoms were right skewed so log transformations were carried out and were successful 
in producing normal residuals for all analyses. 
Impulsivity. At the initial visit, participants completed the UPPS-P Trait 
Impulsivity Scale, a 59-item questionnaire that assesses five components of trait 
impulsivity (i.e. Positive Urgency [positive affect-driven rash action], Negative Urgency 
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[negative affect-driven rash action], Lack of Planning [action without careful thinking], 
Lack of Perseverance [inability to remain with a task through completion], and Sensation 
Seeking [tendency to seek adventure; Whiteside & Lynam, 2001]). The scale has 
demonstrated reliability and validity for use in assessing young adults (Lynam et al., 
2006; Cyders et al., 2007). In the current sample, Lack of Perseverance exhibited fair 
reliability (α = .56) and Lack of Premeditation, Negative Urgency, Positive Urgency and 
Sensation Seeking exhibited good reliability (α = .82-.93). 
Risk-taking Behaviors. Each morning, participants reported detailed information 
about sexual behaviors (new sexual partners), drug use (marijuana and other recreational 
drugs), and the number of units of alcohol that they had consumed in the past 24 hours 
using an adaptation of the Timeline Followback Interview (Sobell & Sobell, 1992; 1994). 
This interview has good reliability and validity in this population (Tonigan, Miller, & 
Brown, 1997) and for this purpose (Del Boca, Darkes, Greenbaum, & Goldman, 2004). 
Due to the limited frequencies of drug use (17 reports, .4% of days) and risky sex (3 
reports, .01% of days) in the sample, it was not possible to examine these outcomes. 
Units of alcohol were defined as one shot, one beer, or one glass of wine. Two daily 
binary outcomes were defined from this response: first, whether or not the woman drank 
alcohol at all, and second, whether the woman drank 4 or more drinks (binge drinking). 
Although binge drinking has been defined in a variety of ways, this corresponds to the 
definition provided by the CDC (http://www.cdc.gov/alcohol/fact-sheets/binge-
drinking.htm). Because drinking was expected to follow a weekly cycle in which alcohol 
use is substantially higher on Thursday through Saturday, with intermediate levels of 
drinking on Sunday, and much lower levels of drinking Monday through Thursday (Del 
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Boca, Darkes, Greenbaum, & Goldman, 2004), day of week was also examined in 
analyses involving drinking utilizing a dichotomous predictor of weekend status (where 
Thursday through Sunday = 1).  
17β-Estradiol and Progesterone. Saliva samples were collected via passive 
drool by participants in the morning thirty minutes after waking and were subsequently 
frozen. Participants were instructed not to eat, drink, brush teeth, or smoke before saliva 
collection. No participant reported violation of this morning protocol in daily diaries. 
Samples from every other day were analyzed due to cost. Serum E2 (pg/mL) and P4 
(pg/mL) were determined using enzyme immunoassay kits available through Salimetrics 
and assayed through campus Clinical Center for Translational Science.  For E2, the 
Salimetrics 17β-Estradiol immunoassay kit had a sensitivity of 0.1 pg/mL and high 
precision (% coefficient of variation ranging from .7 to 14.5). For P4, the Salimetrics 
immunoassay kits had a sensitivity of 5 pg/mL (from 0) and precision of percent 
coefficient of variation between 1.05 and 14.8. All participants showed peak P4 levels 
consistent with an ovulatory cycle (Howards et al., 2009). Finally, E2 and P4 generally 
showed expected trajectories across the menstrual cycle such that E2 demonstrated a 
midcycle peak and secondary peak during the midluteal phase, and P4 was low during the 
follicular phase and peaked during the luteal phase.  
 Menstrual Cycle Phase Coding. First, we coded the follicular, midluteal, and 
premenstrual phase menstrual cycle days using methods described by Edler, Lipson, & 
Keel (2007). The first day of menses was coded as 1; from this day 1, cycle day was 
counted backward to -15, and forward to +10. There was no day 0. Cycle phases were 
coded as Follicular (days +3 to +7), Midluteal (-9 to -5) and Premenstrual (-3 to +1). In 
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addition to these traditional menstrual cycle coding methods, we created an additional 
cycle phase variable to further differentiate pre-ovulatory and post-ovulatory phases. To 
create this variable, we identified four pre-E2 peak and four post-E2 peak days: after 
identifying the ovulatory E2 peak, the day of the ovulatory E2 peak and the three days 
prior comprised the “preovulatory” phase, while the four days after the ovulatory peak 
comprised the “postovulatory” phase. Therefore, five total phases were coded, with no 
overlap: Follicular, Preovulatory, Postovulatory, Midluteal, and Premenstrual.  
Analytic Plan 
	  
 Operationalization of Predictor and Outcome Variables. Each participant had 
two E2 variables and two P4 variables: (1) Between-Person Variables: the person’s 
average levels of E2 and P4 across all samples (“trait” variance in each hormone across 
one menstrual cycle) and (2) Within-Person Variables: the standardized deviation of 
today’s E2 and P4 values from a woman’s average levels of E2 and P4 across all samples 
(i.e., today’s hormone value minus the “person average” for that hormone, divided by the 
person’s standard deviation for that hormone; see Klump et al., 2008). The latter 
standardized deviation reflects fluctuations in E2 and P4 relative to the person’s own 
average level and one’s own typical degree of variability and was the central within-
person predictor. Hormones were also lagged such that hormonal predictors of today’s 
ADHD outcomes represented hormone levels two days ago, and hormonal predictors of 
today’s drinking outcomes (analyzed in the subsample of 22 women reporting drinking 
any alcohol) represented levels one day ago. We made this decision because participants 
responded to questions about their drinking “over the last 24 hours” during morning 
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surveys and to questions about ADHD symptoms and impulsivity about “today” during 
evening surveys. All continuous between-person predictors were standardized. 
Multilevel Logistic Models. Data were analyzed using multilevel models in SAS 
PROC MIXED and SAS PROC GLIMMIX in which repeated daily measures (outcomes, 
hormones) were nested within women. Multilevel models utilize all available data with 
no listwise deletion and accommodate missing data using maximum likelihood 
estimation. In daily models, day-level hormonal predictors were person-standardized 
around each woman’s average and standard deviation to isolate the within-person 
component and create a averageingful scale for estimates.  
To evaluate the unique contributions of between- and within-person variance in 
ovarian hormones to ADHD symptoms, normal multilevel models were utilized 
predicting daily outcomes (ADHD symptoms and drinking) in SAS PROC MIXED. In 
each of these multilevel models, predictors were: 1) standardized BMI as a person-level 
covariate, 2) one’s average E2 (across all observations), 3) one’s average P4 (across all 
observations), 4) person-standardized E2 two days before the outcome, 5) person-
standardized P4 two days before the outcome, and 6) the interaction of person-
standardized E2 and P4.  Both between-person predictors  (one’s average E2 and P4) and 
within-person predictors (person standardized E2 and P4 at the current assessment point) 
were entered into the same model (see tables 3.1-3.5). 
In order to explore whether person-standardized ovarian hormones (fluctuations 
relative to one’s individual average and SD) were more strongly associated with daily 
ADHD symptoms for those with higher trait levels of impulsivity, multilevel regression 
models were again utilized predicting each outcome from 1) standardized BMI as a 
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covariate, 2) one’s average levels of E2 and P4 (as a control variables), 3) person-
standardized recent E2 and P4, and 4) their interaction, 5) trait levels of impulsivity, and 
6) the interactions of all hormone variables with trait impulsivity. 
Drinking outcomes were analyzed in logistic multilevel models in SAS PROC 
GLIMMIX. Daily drinking outcomes were predicted from 1) standardized BMI and legal 
drinking status (0 = Underage 1 = Legal Age) as person-level covariates, 2) dichotomous 
weekend status (Thursday-Sunday = 1; Monday-Wednesday=0, 3), average E2 and P4 
(across all observations), 4) yesterday’s person-standardized levels of E2, 5) yesterday’s 
person-standardized levels of P4, 6) their interaction, and 7) the two- and three-way 
interactions of steroid levels with weekend status. 
Statistical Power. For all analyses, power was adequate (.8) to detect moderate 
effect sizes (d =.07-.09; Klump et. al., 2013) based on the current sample size (N =32). In 
order to reach power to detect small effect size (d=.02), 2000 observations from 145 
women would be needed. For ADHD outcomes (full sample; normal multilevel models), 
intraclass correlation coefficients for both daily hyperactive/impulsive symptoms (ICC = 
.27) and daily inattentive symptoms (ICC = .36) indicated that the majority of the 
variance in ADHD symptoms was at the within-person level, leading to an adjusted N of 
95 observations for the hyperactive/impulsive outcome, and an adjusted N of 76 
observations for the inattention outcome. The smallest detectible effect sizes, assuming a 
normally distributed outcome, for a cross-level interaction predicting daily 
hyperactivity/impulsivity (f squared = .091) and daily inattention (f squared = .085) 
indicated sufficient power to detect conventionally small-to-medium interactive effects of 
UPPS traits and within-person hormone variables. 
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For drinking outcomes, intraclass correlation coefficients for both daily drinking 
(ICC = .15) and daily binge drinking (ICC = .23) also indicated that the majority of the 
variance in drinking was at the within-person level, leading to an adjusted N of 140 
observations for the daily drinking outcome, and an adjusted N of 95 observations for the 
daily binge drinking outcome. Detectible ranges of effect sizes (in this case, odds ratios) 
in logistic models predicting drinking (ORs below .58 and ORs above 1.71) and binge 
drinking (ORs below .51 and ORs above 1.94) indicated sufficient power to detect 
conventionally small-to-medium main effects of a within-person hormonal predictor in a 
model in which other predictors account for 25% of the variance in drinking. 
CHAPTER THREE: RESULTS 
	  
Descriptive Analyses 
	  
The full sample (N=32) included 1058 response days, with 476 outcome days 
included in analyses (i.e., days with nonmissing lagged hormonal predictors). 22 women 
in the sample reported alcohol use with similar demographics as the full sample. The 
subsample included 707 total days, with 352 outcome days included in analyses (i.e., 
days with non-missing lagged hormonal predictors). Among women who reported 
drinking, there were 97 total daily drinking reports (13.7% of days range = 0-15 days of 
drinking) and 31 binge drinking reports (4.3% of days).  
Association of Hormone Averages, Trait Impulsivity & Trait ADHD Symptoms 
 Despite the small degree of between-person variance noted in ADHD symptoms, 
spearman rank partial correlations examined the associations of average ADHD symptom 
reports with average levels of E2 and P4 across the data collection period (controlling for 
both age and BMI). Higher total exposure to E2 and P4 were associated with lower 
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average inattention. E2 exposure, but not total P4 exposure, was associated with lower 
average hyperactivity/impulsivity. Average E2 was uncorrelated with any impulsivity 
measures, but total P4 exposure was negatively associated with Positive Urgency, 
Sensation Seeking, and Lack of Premeditation.  
Effects of E2 and P4 on ADHD Symptoms 
	  
 The model included both between-person and within-person ovarian hormone 
variables as predictors of daily ADHD symptoms (Inattentive, Hyperactive-Impulsive, 
and total ADHD symptoms). In other words, three separate models were conducted in 
which these different symptom domains were independently predicted as a function of 
one’s average levels of both E2 and P4 across the menstrual cycle, from women’s person-
standardized E2 and P4 fluctuations around their own average, and the within-person 
interaction of E2 and P4. Model effects reported throughout this manuscript were not 
substantially altered in significance or effect size when random effects of within-person 
hormonal predictors were added to the multilevel models. However, these random effects 
of within-person hormonal predictors did not significantly improve model fit (as 
evaluated using a likelihood ratio test) and were therefore dropped from the models. 
Results of this model are presented in Table 3.1 and are summarized in the paragraphs 
that follow.  
 There was just one significant between-person effect of average hormones on 
ADHD symptoms. As hypothesized, lower average E2 across the month predicted higher 
average endorsement of daily hyperactive-impulsive ADHD symptoms across the month. 
Within a given person, person-standardized E2 and P4 interacted to predict daily total 
ADHD symptoms in total, including both inattention and hyperactivity-impulsivity. The 
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pattern of this interaction was identical across these three outcomes, and each of these 
interactions are depicted in Figure 3.1. When P4 was higher than usual, lower person-
standardized E2 was associated with more current total ADHD symptoms (γ = -.08, SE = 
.03, t(393) = -2.77, p = .005; when P4 is +1 person-SD above the person average, a +1 
person-SD above one’s person average E2 corresponds to an average decease of .08 in 
ADHD symptoms), hyperactive/impulsive symptoms (γ = -.06, SE = .02, t(390) = -2.93, p 
= .003; when P4 is at +1 person-SD above the person average, a +1 person-SD above 
one’s person average E2 corresponds to an average decrease of .06 in 
hyperactive/impulsive symptoms), and inattentive symptoms (γ = -.05 SE = .02, t(424) = 
-1.99, p = .049; when P4 is at +1 person-SD above the person average, a +1 person-SD 
above one’s person average E2 corresponds to an average decrease of .05 in inattentive 
symptoms), consistent with a post-ovulatory, luteal phase effect of E2. The effects of 
person-standardized E2 were not significant when P4 was lower than usual (all p’s > 
.34). Phase analyses showed similar results, in that inattentive symptoms were 
significantly higher during the postovulatory period than follicular phase (p= .03; see 
Figure 3.2). Although statistically significant, these unmoderated (average) hormonal 
effects are quite small when considered in light of the possible ranges of the outcomes (0-
9 for each subscale and 0-18 for the total score). 
Moderation of Hormone Effects by Trait Impulsivity 
	  
 Negative and Positive Urgency. Both Positive and Negative moderated average 
E2 and the interaction between recent E2 and P4 predicting ADHD outcomes. There was 
a significant interaction between both types of Urgency and average levels of E2 
predicting all ADHD symptoms outcomes and between both types of Urgency and the 
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interaction of recent levels of E2 and P4 predicting ADHD outcomes; each of these 
interactions took the same form, which are depicted in Figures 3.3 through 3.7.  
However, further examination revealed that these effects were significant only for those 
women who were high in either Positive or Negative Urgency (all p’s < .016).  Results of 
analyses probing these interactions revealed that, at high levels of Positive or Negative 
Urgency, lower average E2 across the cycle was associated with increased ADHD 
symptoms. None of these effects of E2 were significant among women low in Negative 
Urgency (all p’s > .39) or low in Positive Urgency (all p’s > .59).  
 To further decompose these three-way interactions, we tested the simple effects of 
recent E2 on each outcome at both lower-than-average (-1 person-SD below the person 
average of P4) and higher-than-average (+1 person-SD above the person average of P4) 
P4 among women high (+1 SD) in trait Urgency. The simple effects of lower-than-
average E2 leading to higher ADHD symptoms were significant only at higher-than-
average P4 (e.g., the luteal phase; all p’s < .025). This was true for both Negative and 
Positive Urgency. At lower-than-average P4 (i.e., the follicular phase) among women 
with high Positive or Negative Urgency, simple effects of recent E2 were not significant 
(all p’s < .27).  
 Phase analyses revealed that for those high in Negative Urgency, inattentive 
symptoms peaked in the post-ovulatory phase relative to the follicular, pre-ovulatory 
midluteal phase and premenstrual phases (see Figure 3.8). Similarly, for those high in 
Positive Urgency, inattentive and hyperactive-impulsive symptoms peaked during the 
postovulatory phase  (see Figure 3.9).  
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 Sensation Seeking. There were no significant interactions between Sensation 
Seeking and average levels of E2 or P4 predicting any ADHD symptoms outcomes. 
However, there were significant interactions between Sensation Seeking, Recent E2, and 
Recent P4 predicting all ADHD symptoms; each of these interactions are presented in 
Figure 3.10.  The two-way interaction between recent E2 and recent P4 was significant 
only among women who were high (+1 SD) in Sensation Seeking. The three-way 
interaction was explored in the same manner described above.  
 The simple effects of lower-than-average E2 leading to higher ADHD symptoms 
were significant only at higher-than-average P4 (e.g., the luteal phase) among women 
with high Sensation Seeking. At lower-than-average P4 (i.e., the follicular phase) among 
women with high Sensation Seeking, simple effects of recent E2 were not significant (all 
p’s < .15).  
 Phase analyses revealed a decrease in inattentive and hyperactive-impulsive 
symptoms during the pre-ovulatory phase for those high or low in Sensation Seeking; 
however, symptoms were lowest during the premenstrual phase than any other phase. 
There was also a peak in symptoms during the post-ovulatory phase for those high in 
Sensation Seeking (see Figure 3.11). 
 Lack of Premeditation and Lack of Perseverance. Lack of Premeditation did 
not moderate any hormone effects on ADHD symptoms. Lack of Perseverance moderated 
just one effect; among women high in Lack of Perseverance (+1 SD above sample 
average), higher average E2 was associated with lower hyperactive/impulsive symptoms 
(γ = -.22 SE = .07, t(30) = -3.11, p = .004); the effect of average E2 was not significant 
among women with low Lack of Perseverance (-1 SD below sample average).  
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 Phase analyses revealed a significant decrease in inattentive symptoms during the 
premenstrual phase and a peak in symptoms during the post-ovulatory phase for those 
high in Lack of Premeditation (see Figure 3.13).  
 Effect Size of Trait Moderators. Results of follow-up probing analyses reveal 
that women with high sensation seeking, positive urgency, or negative urgency, when P4 
is +1 person-SD above the person average, experience a change of roughly .10-.20 (one 
tenth to one twenthieth) of an ADHD symptom with a 1 person-SD change in E2.  
Effects of E2 and P4 on Alcohol Use 
	  
The second set of models focused on hormone variables as predictors of alcohol 
use in the subsample of 22 women. For the multilevel model on this subsample, hormone 
predictors and covariates were the same as above, but also included the covariate of legal 
drinking status and the dichotomous predictor of weekend status (where Thursday 
through Sunday = 1) Results of this model are presented in Table 3.7 (alcohol use), and 
are summarized in the paragraphs that follow.  
 There were no significant between-person correlations of an individual’s 
proportion of drinking days and their average levels of E2 or P4 (all p’s < .45 in full 
sample; all p’s < .36 in drinking subsample). However, within-person results of models 
predicting both daily drinking and daily binge drinking from person-standardized E2 and 
P4 levels (one day prior to drinking outcome), and interactions of E2 and P4 with 
weekend status are presented in Table 3.7. Significant interactions are depicted in Figure 
3.14 and are further characterized using simple slope analyses at the bottom of Table 3.7.  
There were significant three-way interactions between weekend status, E2, and P4 
predicting both drinking and binge drinking. Hormones were predictive of drinking 
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outcomes only on weekend days. Simple slope analyses, presented at the bottom of Table 
3.7, indicated that higher-than-average E2 on weekend days predicted a greater likelihood 
of drinking and binge drinking; these effects of E2 were strongest when P4 was lower 
than usual, and were attenuated but still significant when P4 was higher than usual. A one 
person-SD elevation above the person average of E2 was associated with a 26% increase 
in the probability of drinking, and was associated with a 125% increase in the probability 
of binge drinking when P4 was 1 person-SD below the person average. A similar 
elevation of E2 was associated with a 19% increase in the probability of drinking and a 
27% increase in the probability of binge drinking when P4 was 1 person-SD above the 
person average. Thus, elevated P4 attenuated the effects of E2 elevations on increased 
drinking on weekend days. Extrapolating the size of the effects reported in Table 3.2, 
indicates that ovulation is associated with a 657% increase in odds of binge drinking on 
the weekend (Odds Ratio = 7.57 for a 2.5 person-SD elevation in E2 above one’s person 
average, at 1-SD below the P4 person average). Phase analyses were in line with these 
results, showing a peak in drinking during the pre-ovulatory phase, when E2 is increasing 
dramatically (see Figure 3.15).  
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Table 3.1 
 
 
Main Effects of Between- and Within-Person Ovarian Hormones on Daily Outcomes 
 
Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two 
days prior to the outcome, calculated as today’s hormone value minus the woman’s 
average value for that hormone across the entire cycle, divided by the woman’s standard 
deviation for that hormone across the entire cycle. BMI, Average E2, and Average P4 are 
sample-standardized.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Outcome  (Range of Scale) 
Parameter ADHD Sx (0-18) 
Hyper/Imp 
Sx 
(0-9) 
Inattentive Sx 
(0-9)  
  
Intercept .19 (.15) .09 (.10) .11 (.10)  
BMI .003 (.01) .002 (.004) .003 (.004)  
Average E2 -.08 (.04) -.06* (.03) -.05 (.03)  
Average P4 -.004 (.04) .02 (.03) -.02 (.03)  
Recent E2 -.04 (.02) -.03* (.01) -.01 (.02)  
Recent P4 .02 (.03) .03* (.02) -.001 (.02)  
Recent E2 X P4 -.05* (.02) -.03* (.01) -.04* (.02)  
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Table 3.2 
 
Interactive Effects of Trait Negative Urgency and Ovarian Hormone Predictors on Daily 
ADHD Symptoms 
 
 
Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two 
days prior to the outcome, calculated as today’s hormone value minus the woman’s 
average value for that hormone across the entire cycle, divided by the woman’s standard 
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and 
Negative Urgency (NU) are sample-standardized.  
 
  Outcome (Scale)  
Parameter Total ADHD SX Hyperactive Sx Inattentive Sx 
 Estimate SE Estimate SE Estimate SE 
Intercept 0.22** 0.05 0.10** 0.03 0.15** 0.04 
BMI 0.00 0.05 0.00 0.02 0.00 0.04 
Average E2 -0.11 0.06 -0.06 0.03 -0.08 0.05 
Average P4 -0.02 0.06 0.01 0.03 -0.03 0.05 
Recent E2 -0.03 0.02 -0.03 0.01 -0.02 0.02 
Recent P4 0.03 0.02 0.04** 0.01 0.01 0.02 
Recent E2 X Recent P4 -0.06** 0.02 -0.04** 0.01 -0.04** 0.02 
Trait Negative Urgency (NU) 0.17** 0.06 0.08* 0.03 0.13* 0.05 
NU X Trait E2 -0.15* 0.06 -0.09* 0.03 -0.10* 0.05 
NU X Trait P4 -0.09 0.08 -0.02 0.04 -0.09 0.06 
NU X Recent E2 -0.02 0.02 -0.03 0.02 -0.02 0.02 
NU X Recent P4 0.05 0.03 0.05** 0.02 0.02 0.02 
NU X Recent E2 X Recent P4 -0.08** 0.02 -0.04** 0.01 -0.06** 0.02 
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Table 3.3 
 
Interactive Effects of Trait Positive Urgency and Ovarian Hormone Predictors on Daily 
ADHD Symptoms 
 
 
Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two 
days prior to the outcome, calculated as today’s hormone value minus the woman’s 
average value for that hormone across the entire cycle, divided by the woman’s standard 
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and 
Positive Urgency (PU) are sample-standardized.  
  Outcome (Scale)  
Parameter Total ADHD SX Hyperactive Sx Inattentive Sx 
 Estimate SE Estimate SE Estimate SE 
Intercept 0.25** 0.04 0.13** 0.02 0.17** 0.03 
BMI -0.03 0.03 -0.01 0.02 -0.02 0.03 
Average E2 -0.18** 0.04 -0.10** 0.03 -0.13** 0.03 
Average  P4 0.05 0.04 0.06* 0.03 0.01 0.03 
Recent E2 -0.02 0.02 -0.02 0.01 0.00 0.02 
Recent P4 0.02 0.02 0.03* 0.01 -0.01 0.02 
Recent E2 X Recent P4 -0.05** 0.02 -0.03* 0.01 -0.04* 0.02 
Trait Positive Urgency (PU) 0.24** 0.04 0.12** 0.03 0.19** 0.03 
PU X Average E2 -0.23** 0.04 -0.12** 0.03 -0.17** 0.03 
PU X Average P4 -0.02 0.04 0.03 0.03 -0.04 0.03 
PU X Recent E2 0.00 0.02 -0.01 0.01 0.01 0.02 
PU X Recent P4 0.03 0.02 0.04* 0.02 0.01 0.02 
PU X Recent E2 X P4 -0.06** 0.02 -0.03* 0.01 -0.06** 0.02 
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Table 3.4 
 
Interactive Effects of Trait Sensation Seeking and Ovarian Hormone Predictors on Daily 
ADHD Symptoms 
 
 
Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two 
days prior to the outcome, calculated as today’s hormone value minus the woman’s 
average value for that hormone across the entire cycle, divided by the woman’s standard 
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and 
Sensation Seeking (SS) are sample-standardized.  
  Outcome (Scale)  
Parameter Total ADHD SX Hyperactive Sx Inattentive Sx 
 Estimate SE Estimate SE Estimate SE 
Intercept 0.21** 0.05 0.11** 0.03 0.14** 0.04 
BMI 0.09 0.06 0.05 0.03 0.07 0.05 
Average E2 -0.11 0.06 -0.07* 0.03 -0.08 0.04 
Average P4 0.07 0.06 0.07 0.03 0.03 0.05 
Recent E2 -0.01 0.02 -0.02 0.01 0.00 0.02 
Recent P4 0.01 0.02 0.03 0.01 -0.01 0.02 
Recent E2 X Recent P4 -0.05* 0.02 -0.03* 0.01 -0.04* 0.02 
Trait Sensation Seeking (SS) 0.17** 0.06 0.10** 0.03 0.13** 0.05 
SS X Average E2 0.01 0.09 -0.02 0.05 0.01 0.07 
SS X Average P4 -0.14 0.12 -0.02 0.07 -0.12 0.09 
SS X Recent E2 -0.01 0.02 -0.01 0.01 -0.01 0.02 
SS X Recent P4 0.03 0.02 0.03* 0.02 0.02 0.02 
SS X Recent E2 X P4 -0.05* 0.02 -0.03* 0.01 -0.05** 0.02 
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Table 3.5 
 
Interactive Effects of Trait Lack of Premeditation and Ovarian Hormone Predictors on 
Daily ADHD Symptoms 
 
 
Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two 
days prior to the outcome, calculated as today’s hormone value minus the woman’s 
average value for that hormone across the entire cycle, divided by the woman’s standard 
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and 
trait Lack of Premeditation (LPM) are sample-standardized.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  Outcome (Scale)  
Parameter Total ADHD SX Hyperactive Sx Inattentive Sx 
 Estimate SE Estimate SE Estimate SE 
Intercept 0.21** 0.06 0.12** 0.04 0.14** 0.05 
BMI 0.00 0.06 0.01 0.03 -0.01 0.04 
Average E2 -0.12 0.07 -0.09* 0.04 -0.08 0.05 
Average P4 0.00 0.08 0.05 0.05 -0.04 0.06 
Recent E2 -0.01 0.02 -0.02 0.01 0.00 0.02 
Recent P4 0.02 0.02 0.03* 0.02 0.00 0.02 
Recent E2 X Recent P4 -0.05** 0.02 -0.03* 0.01 -0.04** 0.02 
Trait Lack of Premed (LPM) 0.06 0.08 0.03 0.04 0.05 0.06 
LPM X Average E2 -0.11 0.07 -0.06 0.04 -0.08 0.05 
LPM X Average P4 -0.06 0.08 0.01 0.04 -0.08 0.06 
LPM X Recent E2 0.00 0.03 -0.01 0.02 0.00 0.02 
LPM X Recent P4 0.03 0.03 0.02 0.02 0.03 0.02 
LPM X Recent E2 X P4 -0.03 0.02 -0.01 0.02 -0.03 0.02 
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Table 3.6 
 
Interactive Effects of Trait Lack of Perseverance and Ovarian Hormone Predictors on 
Daily ADHD Symptoms 
 
 
Note. **p < .01, *p < .05. Recent E2 and P4 are person-standardized values from two 
days prior to the outcome, calculated as today’s hormone value minus the woman’s 
average value for that hormone across the entire cycle, divided by the woman’s standard 
deviation for that hormone across the entire cycle. BMI, Average E2, Average P4, and 
Trait Lack of Perseverance (LPS) are sample-standardized.  
  Outcome (Scale)  
Parameter Total ADHD SX Hyperactive Sx Inattentive Sx 
 Estimate SE Estimate SE Estimate SE 
Intercept 0.22** 0.06 0.10** 0.03 0.16** 0.05 
BMI -0.01 0.06 -0.01 0.03 0.00 0.05 
Average E2 -0.08 0.06 -0.06 0.03 -0.05 0.05 
Average P4 -0.01 0.07 0.02 0.03 -0.03 0.06 
Recent E2 -0.03 0.02 -0.02 0.01 -0.01 0.02 
Recent P4 0.01 0.02 0.03 0.01 0.00 0.02 
Recent E2 X Recent P4 -0.04* 0.02 -0.02** 0.01 -0.03 0.02 
Trait Lack of Persev (LPS) 0.12 0.07 0.05 0.04 0.10 0.06 
LPS X Average E2 -0.17 0.09 -0.13** 0.04 -0.10 0.07 
LPS X Average P4 0.06 0.09 0.08 0.05 0.00 0.08 
LPS X Recent E2 -0.01 0.03 -0.02 0.02 0.02 0.02 
LPS X Recent P4 0.00 0.03 0.00 0.02 -0.02 0.02 
LPS X Recent E2 X P4 -0.01 0.03 0.01 0.02 -0.01 0.02 
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Table 3.7 
 
 
Models Predicting Daily Alcohol Use from Weekend Status and Recent Ovarian Steroid 
Levels  
 
Note. *p < .05, **p < .01, ***p < .001. All hormones are standardized within person and 
calculated as today’s value minus one’s person average, divided by one’s person standard 
deviation. E2 = Estradiol, P4 = Progesterone. Low P4 = 1 standard deviation below the 
person average; High P4 = 1 standard deviation above the person average. Significant 
fixed effects are shown in bold. 
 
 
 
 
 
 Outcome  
Parameter 
Daily Alcohol Use Daily Binge Drinking  (>=4 Drinks) 
Estimate SE Estimate SE 
Intercept -2.33** 0.40 -4.72** 0.85 
BMI 0.11 0.22 -.20 .65 
Legal Drinking Status 0.14* 0.06 0.02 .69 
Weekend Status 0.93* 0.37 2.20* 0.71 
Recent E2  0.28* 0.12 1.00** 0.33 
Recent P4 -0.08 0.18 0.37* 0.18 
Recent E2 ×  Recent P4 -0.08 0.12 -0.05 0.22 
Wknd ×  Recent E2 0.00 0.01 -0.33 0.59 
Wknd ×  Recent P4 0.00 0.28 -0.99** 0.38 
Wknd ×  Recent E2 ×  Recent P4 0.04** 0.01 -0.12* 0.06 
 
Simple Effects of Within-Person E2 Levels on the Weekend 
 
At Low P4 0.23* 0.11 0.81* 0.36 
         Odds Ratio (95% CI) 1.25 (1.02 to 1.56) 2.24 (1.11 to 4.55) 
     
At High P4 0.17* 0.083 0.24* 0.11 
         Odds Ratio (95% CI) 1.18 (1.01 to 1.39) 1.27 (1.02 to 1.57) 
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Figure 3.1. Interactive Effects of Person-Standardized Recent E2 and P4 on ADHD 
Symptoms in Women Across One Menstrual Cycle.  
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Figure 3.2. Phase analyses of Hyperactive-Impulsive Symptoms (TOP) and Inattentive 
Symptoms (BOTTOM). *Indicates a significant difference (p < .05) between phases.  
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Figure 3.3. Interactive Effects of Trait Negative Urgency and Average E2 on Average 
Daily ADHD Symptoms in Women Across One Menstrual Cycle.  
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Figure 3.4. Interactive Effects of Trait Negative Urgency with Recent E2 and P4 (Person-
Standardized) on Daily ADHD Symptoms in Women Across One Menstrual Cycle. 
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Figure 3.5. Interactive Effects of Trait Positive Urgency and Average E2 on Average 
Daily ADHD Symptoms in Women Across One Menstrual Cycle.  
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Figure 3.6. Interactive Effects of Trait Positive Urgency and Average P4 on Average 
Daily Hyperactive Symptoms in Women Across One Menstrual Cycle.  
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Figure 3.7. Interactive Effects of Trait Positive Urgency with Recent E2 and P4 (Person-
Standardized) on Daily ADHD Symptoms in Women Across One Menstrual Cycle.  
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Figure 3.8. Phase analyses of Inattentive Symptoms for those high and low in trait 
Negative Urgency (there was no significant variability for Hyperactive-Impulsive 
Symptoms). *Indicates a significant difference (p < .05) between phases for the full 
sample. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*	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Figure 3.9. Phase analyses of Hyperactive-Impulsive Symptoms (TOP) and Inattentive 
Symptoms (BOTTOM) for those high and low in trait Positive Urgency. *Indicates a 
significant difference (p < .05) between phases for the full sample. 
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Figure 3.10. Interactive Effects of Trait Sensation Seeking with Recent E2 and P4 
(Person-Standardized) on Daily ADHD Symptoms in Women Across One Menstrual 
Cycle.
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Figure 3.11. Phase analyses of Hyperactive-Impulsive (TOP) and Inattentive (BOTTOM) 
Symptoms for those high and low in trait Sensation Seeking.  *Indicates a significant 
difference (p < .05) between phases for the full sample. 
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Figure 3.12. Interactive Effects of Trait Lack of Perseverance and Average E2 on 
Average Daily Hyperactive Symptoms in Women Across One Menstrual Cycle.  
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Figure 3.13. Phase analyses of Inattentive Symptoms for those high and low in trait Lack 
of Premeditation (there was no significant variability in Hyperactive-Impulsive 
symptoms). *Indicates a significant difference (p < .05) between phases for the full 
sample. 
 
*	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Figure 3.14. Interactive Within-Person Effects of Recent E2 Levels and Recent P4 Levels 
on Drinking (TOP) and Binge Drinking (BOTTOM) on Weekend Days  
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Figure 3.15. Phase analyses for probability of drinking (TOP) and binge drinking 
(BOTTOM) across the cycle. *Indicates a significant difference (p < .05) between 
phases.  
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CHAPTER FOUR: DISCUSSION 
	  
Although research suggests that women with ADHD may exhibit greater 
impairment at puberty, no prior study has directly examined circulating hormone levels in 
relation to ADHD symptoms and other risk-taking behaviors in young adulthood, the 
goals of the present study. In line with prior work on hormones and EF and in line with 
study hypotheses, lower average between-person levels of E2, and periods of lower-than-
average E2 across the cycle, increased risk for ADHD symptoms. However, results 
demonstrated the importance of interactions between E2 and P4. Within-person effects of 
low E2 were only significant when recent P4 was also higher-than-average (i.e. in the 
luteal phase). Specifically, women with lower-than-average levels of E2 reported higher 
hyperactive-impulsive symptoms during periods of higher concurrent levels of P4. 
Further, somewhat in line with study hypotheses, only women who were high on the 
traits of negative urgency, positive urgency, or sensation seeking (but not high in lack of 
perseverance or premeditation) exhibited an association between lower-than-average E2 
levels and high ADHD symptoms. In contrast to study hypotheses, high within-person E2 
was associated with increased drinking particularly in the context of low P4. Overall, 
study results suggest multiple pathways to ADHD symptoms contingent on the 
interactive effects for hormones, at least for women at-risk based on affective personality 
factors, and these effects differ from what is seen in relation to risk-taking behavior such 
as binge drinking. 
Hormonal Effects on ADHD Symptoms 
	  
Results demonstrated that lower-than-average E2 in the context of higher-than-
average P4 is associated with increased symptoms, in line with case studies suggesting 
 
	   50	  
symptoms of ADHD worsen the week before menstruation, when E2 falls from its mid-
luteal peak and P4 is still higher-than-average (Quinn, 2005). In fact, our phase analyses 
suggested an early luteal, or post-ovulatory, increase in ADHD symptoms (seemingly 
driven by post-ovulatory and peri-menstrual reductions in E2). These findings are in line 
with research demonstrating that high E2 facilitates cognitive functioning in women with 
decreases in E2 being risky for cognitive functioning, EF, and attention (Jacobs et al., 
1998; Schmidt et al., 1996; Sherwin, 1997). These effects may be mediated through E2 
effects on the dopamine system, since lower synaptic dopamine and dopamine receptors 
are correlated with lower E2 levels (Archer, 1999; Gibbs, 2010). ADHD is also 
associated with lower extracellular dopamine and medications used to treat ADHD 
increase dopamine levels (Volkow et. al., 2001), but high E2 appears to enhance 
dopamine; thus, it appears to be protective against ADHD symptoms.  In any case, low or 
declining levels of E2 seem to be risky for ADHD symptoms.  
However, these effects of hormones on ADHD symptoms may only be important 
for some women. Somewhat in line with study hypotheses, only women who were high 
on the traits of negative urgency, positive urgency or sensation seeking showed a 
negative association between lower-than-average E2 levels and high ADHD symptoms, 
and only women high on the trait of lack of perseverance showed a negative association 
between average levels of E2 and high hyperactive-impulsive symptoms. In contrast to 
study hypotheses, the other facet of impulsivity, lack of premeditation, did not moderate 
any hormone effects on ADHD symptoms. These urgency-related effects during the 
luteal phase of the menstrual cycle replicate findings from a study of a personality 
phenotype characterized by negative urgency (Borderline Personality Disorder). That 
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study showed an identical pattern of interactive within-person effects of E2 and P4 on 
impulsivity and related psychopathology among women high in trait borderline features 
(Eisenlohr-Moul et al., 2015), which are characterized by a behavioral phenotype highly 
similar to negative urgency (Settles et al., 2012). 
Hormonal Effects on Risk-Taking 
	  
 The results of hormonal effects on drinking were in contrast to study hypotheses 
and results of hormonal effects on ADHD symptoms. The effects of E2 and P4 on alcohol 
use (in the subsample of women who drank alcohol) suggested that higher-than-average 
recent levels of E2, in the co-occurring contexts of (1) lower-than-average P4 (i.e. the 
follicular phase) and (2) during the weekend, were associated with increased risk of 
drinking and binge drinking. Though this effect of E2 was significant at all levels of P4, 
the effect was stronger when P4 was low and weaker when P4 was high, likely reflecting 
the antagonistic influence of P4 on E2 (Singh, Su, & Ng, 2013) and further highlighting 
the importance of the interactions of P4 and E2 (Klump et al., 2008; 2013; Eisenlohr-
Moul et al., 2015). 
 The effects of E2 and P4 on drinking may also be mediated through dopamine and 
GABA. For example, animal studies suggest that high E2 decreases GABA 
neurotransmission, which increases dopamine release in the striatum and nucleus 
accumbens (Becker & Hu, 2008; Lynch, Roth, & Carroll, 2002). Additionally, high E2 
down-regulates dopamine receptor binding (Becker & Hu, 2008). Abnormalities in 
dopaminergic neurotransmission and elevated E2 can increase reward sensitivity, which 
is a key mechanism of substance craving, use, and other risk-taking behaviors (Dreher et 
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al., 2007; Hyman, Malenka, & Nestler, 2006; Koob & Le Moal, 2001; Lofgren et al., 
2009; Robinson & Berridge, 1993; Volkow et al., 2010).  
 Results are consistent with increases in female risk-taking behaviors around 
ovulation, in line with evolutionary developmental theory suggesting that females may be 
more likely to engage in risk-taking behaviors such as alcohol use as they approach 
ovulation, potentiated by rising E2, which might operate to facilitate conception 
(Gangestad, Thornhill, & Garver-Apgar, 2002; Geary, 2010; Larson et al., 2013). This 
might also provide a partial explanation for increases in alcohol use and other risk-taking 
behaviors around puberty (Spear, 2010), again potentiated by rapidly rising levels of sex 
steroids, and at a time when fertility is increasing. Furthermore, such results suggest a 
large impact of environmental influences, such as opportunity for drinking and 
availability of alcohol on weekends on college campuses.  
Clinical Implications 
	  
The present study challenges current research practices by suggesting that ADHD 
symptom presentation in post-pubertal females may fluctuate across the cycle. Perhaps, if 
the presentation of ADHD in post-pubertal women is not static, then it might not 
constitute a true trait, as currently conceptualized in DSM-5 (APA, 2013). Rather, ADHD 
in women might be better conceptualized as a series of states in which some symptoms 
may worsen due to biological changes. Further, it is possible that women may also 
fluctuate through their life -and even within a single month- to the degree that they would 
not always meet DSM-5 criteria for ADHD. Prior work has suggested that women go 
undiagnosed due to the higher incidence of inattentive versus hyperactive-impulsive 
symptoms among women (Gaub & Carlson, 1997; Gershon & Gershon, 2002). However, 
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the present study suggests another alternative. Perhaps some women do not reach 
diagnostic threshold or impairment until hormones rise and begin to cycle at puberty. 
These findings suggest a number of potential implications for the diagnosis and 
treatment of women with ADHD. For example, results support that clinicians may need 
to know a woman’s cycle phase and hormonal status, including medications that affect 
hormone levels like birth control, when assessing ADHD in young women (Quinn & 
Nadeau, 2002). Finally, trait levels of impulsivity may be important to consider in 
assessments, and inclusion of assessment of trait impulsivity may help to identify those 
women who are more at risk for hormonal influences on ADHD symptoms. 
Limitations and Future Directions 
	  
This study has a number of notable strengths as it was the first, to my knowledge, 
to directly and empirically examine associations between E2 and ADHD symptoms, 
associated risk-taking behaviors, and a marker of the disorder, namely impulsivity. 
However, it is not without limitations. Importantly, the present study utilized a 
community (vs. clinical) sample, which may limit the generalizability of these findings, 
despite the fact that research suggests ADHD is best characterized by a continuous 
dimension (Barkley, 2006; Haslam et al., 2006; Larsson, Anckarsater, Råstam, Chang, 
and Lichtenstein, 2012; Marcus & Barry, 2011). The distribution of ADHD symptoms in 
the current sample was positively skewed, and risky behaviors were rare. Future studies 
should include larger samples and include more women meeting diagnostic criteria for 
ADHD and samples with higher rates of drinking, substance use and risky sexual 
behaviors. However, obtaining a sample of women willing and able to complete 35 days 
of data collection successfully was challenging; obtaining a sample of women with 
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ADHD who could also accomplish this task, requiring a high level of conscientiousness 
and organization, would be even more of a challenge. The present study also relied on 
women’s self-report. Future studies could utilize other report measures of symptoms 
(which we had on only a very small subsample of the women) and/or other measures of 
impulsivity and/or impulse control, such as neuropsychological testing.  
Recent experimental work suggests that it may be acute change in E2 or P4 
(rather than higher or lower than average levels) that can have a dysregulating effect on 
brain function and behavior in susceptible women (reviewed in Schiller et al., 2016 and 
Gordon et al., 2015). Therefore, it is possible that the effects of lower-than-average E2 in 
the present study are attributable in part to the acute, day-to-day effects of withdrawal 
from E2 in the luteal phases of vulnerable women. Although post-hoc analyses 
examining the effects of two-day changes in hormones did not reveal a consistent pattern 
of effects, it is possible that the effects of hormone change operate on a shorter lag (e.g., 
24-hour change) than was possible here with every-other-day hormone sampling (i.e., 48-
hour change).  Future work with daily samples of E2 and P4 could assess the degree of 
impact of a 24-hour change in hormones, in addition to relative recent hormone levels 
when assessing their relationship with ADHD symptoms.   
There are numerous other important directions for future work. Due to E2’s 
effects on cognitive functioning and symptoms, results of neuropsychological testing 
could be affected, and this should be examined. Further, the effect of E2 and P4 on 
psychostimulant medication response and efficacy is another important area for future 
research with large clinical implications. Additionally, the effects of birth control on 
ADHD symptoms and psychostimulants are important areas for future research. For 
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example, studies could compare the effects of 21/7 birth control to 24/4 or continuous 
birth control methods, as the latter may decrease fluctuations in P4 and E2 (Sullivan, 
1999) and could be beneficial for women with ADHD. Future studies should also 
examine potentially developmental effects of hormones across different important 
developmental periods (e.g., puberty, menopause) and pregnancy. The present study 
stressed the importance of consideration of interactions between E2 and P4 in line with 
some previous studies (Klump et al., 2008; 2013; Eisenlohr-Moul et al., 2015). Further 
studies should also examine the interaction of other hormones that may affect 
psychopathology and cognition, such as testosterone and dehydroepiandrosterone. 
Incorporating associated genetic factors (e.g. DRD2, COMT etc.) is another promising 
avenue for future research.  
 State impulsivity was not assessed in the present study after data inspection 
revealed data as suspect. The response scale of the state measure of impulsivity, a 
shortened version of UPPS, was coded in such a way that the likert scale was in reverse 
of other measures. Given this finding, and the negative correlation of the state measure to 
the trait UPPS, the data seemed suspect and could not be utilized for analyses. Future 
studies should examine whether state impulsivity mediates the association of hormones 
and ADHD, perhaps due to their similar brain pathways involving the amygdala, 
orbitofrontal cortex, and ventromedial prefrontal cortex (Cyders & Smith, 2008). 
Conclusion 
	  
The present study suggests a great deal of complexity in the presentation of 
ADHD in young adult women. Low levels and decreases in E2 appear to worsen ADHD 
symptoms, challenging the conceptualization of ADHD as a trait, at least in young adult 
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women high in trait impulsivity. These relationships are significant only in the context of 
high P4, and only among women who are high in certain types of trait impulsivity, 
further suggesting ADHD is a heterogeneous disorder characterized by equifinality. 
These results may have implications for assessment and treatment approaches for young 
women with ADHD. 
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